TORONTO, Nov. 1, 2017 /PRNewswire/ -- Ehave, Inc. (OTCQB: EHVVF), a healthcare company dedicated to empowering the mentalhealth community with next-generation digital solutions, today announced the launch of a robust digital patient intake system, in collaboration with MedReleaf Corp. (TSE: LEAF), Canada's premium medical cannabis licensed
Ehave's technology will be integrating with MedReleaf's patient and physician dashboard that is used to establish baseline patient assessments and track patient-reported symptoms by incorporating a broad panel of clinically-validated surveys into a single digital portal. "The core of our business is focused on improving outcomes for our patients and using advanced data-driven technology to support and validate efficacy in cannabis-based medicine," says Neil Closner, CEO of MedReleaf. This first tool will be integrated with future compliance and reporting offerings co-developed by Ehave and MedReleaf that will empower patients in their treatment plans, help both patients and healthcare practitioners to encourage treatment compliance, and verify treatment outcomes in a reliable and objective manner.
"We're pleased to advance our flagship collaboration with MedReleaf and launch this first product offering for the investigation of cannabis-based therapies," said Prateek Dwivedi, CEO of Ehave. "Our core data management technology allows us to incorporate and centralize any number of validated or novel patient assessments and surveys into various formats such as our Ehave Connect clinician portal, customized Apps, engaging video games, and other digital platforms. The true power of our technology is in our ability to objectively capture patient outcomes in response to therapy, irrespective of the specific condition, format, or therapy. This provides a pathway to clinical validation for emerging treatment modalities such as medical cannabis, where efficacious dosing and administration remains to be established by clinician and regulatory standards."
About Ehave, Inc. Ehave is empowering the mental healthcare community with a next-generation of data-rich tools designed to improve patient management, diagnosis and treatment. With Ehave Connect, Ehave's mental health informatics platform, clinicians can make objective, data-driven decisions while keeping patients informed and engaged throughout their mental healthcare journey. Ehave Connect offers a powerful set of core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health Systems ("MHS"), a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder ("ADHD"), through its collaboration with the Hospital for Sick Children ("SickKids"). Ehave Connect is also being utilized to advance the validation and optimization of medical cannabis, through its collaboration with MedReleaf. For more information, visit https://www.ehave.com/.
Forward-Looking Statement Disclaimer This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company's research, manufacturing and other development efforts; (ii) the Company's ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company's products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company's industry and introduction of competing products; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.'s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.
Contacts Tiberend Strategic Advisors, Inc. Joshua Drumm, Ph.D. (Investors) (212) 375-2664 firstname.lastname@example.org
Janine McCargo (Media) 646-604-5150 email@example.com
View original content:http://www.prnewswire.com/news-releases/ehave-advances-medreleaf-collaboration-with-launch-of-digital-patient-intake-portal-300547909.html
SOURCE Ehave, Inc.
Subscribe to our Free Newsletters!
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...View All